1-(2-oxo-3-(1-(4-((piperidine-4-carboxamido)methyl)-1H-pyrrol-2-yl)ethylidene)indolin-5-yl)urea(Z)-1-(2-oxo-3-(1-(4-((piperidine-4-carboxamido)methyl)-1H-pyrrol-2-yl)ethylidene)indolin-5-yl)urea

ID: ALA228757

Chembl Id: CHEMBL228757

Cas Number: 1056225-69-4

PubChem CID: 11430140

Max Phase: Preclinical

Molecular Formula: C22H26N6O3

Molecular Weight: 422.49

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1cc(CNC(=O)C2CCNCC2)c[nH]1

Standard InChI:  InChI=1S/C22H26N6O3/c1-12(19-16-9-15(27-22(23)31)2-3-17(16)28-21(19)30)18-8-13(10-25-18)11-26-20(29)14-4-6-24-7-5-14/h2-3,8-10,14,24-25H,4-7,11H2,1H3,(H,26,29)(H,28,30)(H3,23,27,31)/b19-12-

Standard InChI Key:  DRPJZMIFBAXAKX-UNOMPAQXSA-N

Alternative Forms

1. Parent:

   

   ALA228757

   N-[(5-{1-[(3Z)-5-(carbamoylamino)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]ethyl}-1H-pyrrol-3-yl)methyl]piperidine-4-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 422.49

Molecular Weight (Monoisotopic): 422.2066

AlogP: 2.00

#Rotatable Bonds: 5

Polar Surface Area: 141.14

Molecular Species: BASE

HBA: 4

HBD: 6

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.31

CX Basic pKa: 10.14

CX LogP: 0.30

CX LogD: -2.12

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.41

Np Likeness Score: -0.91

References

1. Islam I, Brown G, Bryant J, Hrvatin P, Kochanny MJ, Phillips GB, Yuan S, Adler M, Whitlow M, Lentz D, Polokoff MA, Wu J, Shen J, Walters J, Ho E, Subramanyam B, Zhu D, Feldman RI, Arnaiz DO..  (2007)  Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517.,  17  (14): [PMID:17544272] [10.1016/j.bmcl.2007.05.060]

2. Das B, Baidya ATK, Mathew AT, Yadav AK, Kumar R..  (2022)  Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,  56  [PMID:35033884] [10.1016/j.bmc.2022.116614]

Source

Source(1):

• Scientific Literature